DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Curis Lifesciences Limited — Agreements

NSE 2 hrs ago·13 Aug 2026, 1:31 pm

Curis Lifesciences

Curis Lifesciences Limited has entered into a joint venture agreement with Curosun Pharmaceutical Nig Ltd, a Nigerian company. Under this deal, Curis will acquire a 49.95% stake in the Nigerian entity.

This strategic move allows Curis to expand its international footprint into the West African market. For investors, this signals the company's intent to diversify its revenue streams beyond its domestic operations and tap into a growing pharmaceutical sector.

Investors should watch for updates on the integration of the new venture and how it impacts the company's overall financial performance in the coming quarters.